Dengue imposes a tremendous public health burden. However, a definitive therapy remains lacking. Despite its severity and the rampant progression of this disease post infection with either of the four dengue serotypes, standard therapeutic measures border around symptomatic relief and supportive care.
Janssen Pharmaceutical Companies reported that a novel, early-stage clinical candidate (JNJ-1802) could be a potent preventive agent against dengue – this Thursday.
Earlier, JNJ-1802 was found to be safe and well-tolerated in animal studies and is active against all four dengue serotypes. The drug is highly effective against two dengue serotypes – DENV-1 and -2, in non-human primates. This pharmaceutical agent has been approved for testing in Phase 2 clinical studies – for dengue prevention.
This drug acts by interfering with viral protein interactions and hence, impedes replications of the virus. Newer research on this drug has confirmed its safety for human use and has proven it efficiency in dengue prophylaxis and treatment.
Subscribe To Our Newsletter
Filter out the noise and nurture your inbox with health and wellness advice that's inclusive and rooted in medical expertise.
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please update your details
Please login to comment on this article